| SEC

S-1/A Form - [Amend] General form for registration of securities under the Securities Act of 1933 - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

S-1/A1fs12019a3_tffpharmaceuticals.htmAMENDMENT NO. 3 TO FORM S-1

As filed with the Securities andExchange Commission on October 11, 2019

Registration No. 333-233378

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

AMENDMENT NO. 3
TO

FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

 

 

 

TFF PHARMACEUTICALS, INC.

(Exact name of registrant as specified inits charter)

 

Delaware   2834   82-4344737
(State or other jurisdiction of
Incorporation or organization)
  (Primary Standard Industrial
Classification Code Number)
  (IRS Employer
Identification Number)

 

2600 Via Fortuna, Suite 360

Austin, Texas 78746

(737) 802-1973

(Address, including zip code, and telephonenumber, including area code, of registrant’s principal executive offices)

 

 

 

Glenn Mattes

President and Chief Executive Officer

TFF Pharmaceuticals, Inc.

2600 Via Fortuna, Suite 360

Austin, Texas 78746

(737) 802-1973

(Address, including zip code, and telephonenumber, including area code, of agent for service)

 

 

 

Copies to:

Daniel K. Donahue, Esq.

Christopher M. Piazza, Esq.

Greenberg Traurig, LLP

3161 Michelson Drive, Suite 1000

Irvine, California 92612

Telephone: (949) 732-6557

 

Kevin K. Leung, Esq.

Dominador D. Tolentino, Jr., Esq.

LKP Global Law, LLP

1901 Avenue of the Stars, Suite 480

Los Angeles, California 90067

Telephone: (424) 239-1890

 

 

 

Approximate dateof commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.

 

Ifany of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 underthe Securities Act of 1933, check the following box. ☐

 

Ifthis Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, pleasecheck the following box and list the Securities Act registration statement number of the earlier effective registration statementfor the same offering. ☐

 

Ifthis Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and listthe Securities Act registration statement number of the earlier effective registration statement for the same offering.

 

Ifthis Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and listthe Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check markwhether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting companyor an “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

    Largeaccelerated filer ☐   Accelerated filer
    Non-acceleratedfiler ☒   Smaller reportingcompany ☒
        Emerging GrowthCompany ☒

 

Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

The Registrant hereby amends thisRegistration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file afurther amendment, which specifically states that this Registration Statement shall thereafter become effective in accordancewith Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as theSecurities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 

 

EXPLANATORYNOTE

 

The sole purposeof this Amendment No. 3 (the “Amendment”) to the Registration Statement on Form S-1 (the “Registration Statement”)of TFF Pharmaceuticals, Inc. is to refile Exhibit 5.1 to the Registration Statement as indicated in Item 16(a) of Part II of thisAmendment. No change is made to the preliminary prospectus constituting Part I of the Registration Statement or Items 13, 14,15, 16(b) or 17 of Part II of the Registration Statement. Accordingly, this Amendment consists only of the facing page, this explanatorynote and Item 16(a) of Part II, including Exhibit 5.1, and the signature page of the Registration Statement.

 

1

 

 

PARTII

 

INFORMATIONNOT REQUIRED IN PROSPECTUS

ITEM 16. EXHIBITS

 

Exhibit No.   Description of Document
1.1*   Form of Underwriting Agreement
3.1*   Second Amended and Restated Certificate of Incorporation of the Registrant
3.2*   Bylaws of the Registrant
3.3*   Amended and Restated Bylaws of the Registrant effective immediately following the closing of this offering
4.1*   Specimen Certificate representing shares of common stock of Registrant
4.2*   Warrant dated January 24, 2018 issued to Liquid Patent Advisors, LLC
4.3*   Warrant dated March 13, 2018 issued to National Securities Corporation
4.4*   Warrant dated March 22, 2018 issued to National Securities Corporation
4.5*   Warrant dated May 16, 2019 issued to National Securities Corporation
4.6*   Warrant dated May 23, 2019 issued to National Securities Corporation
5.1   Opinion of Greenberg Traurig, LLP regarding the validity of the common stock being registered
10.1*   Engagement Agreement dated January 26, 2018 between Liquid Patent Advisors, LLC and the Registrant
10.2*   Securities Purchase Agreement dated March 13, 2018 by and among the Registrant and the Buyers named therein
10.3*   Amended and Restated Registration Rights Agreement dated May 16, 2019 by and among the Registrant and certain of its stockholders
10.4*   Contribution and Subscription Agreement dated January 24, 2018 between the Registrant and Lung Therapeutics, Inc.
10.5*   Patent License Agreement dated July 8, 2015 between Lung Therapeutics, Inc. and The University of Texas at Austin
10.6*+   TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan
10.7*+   Amended and Restated Consulting Agreement dated December 20, 2018 between Robert Mills and the Registrant
10.8*+   Consulting Agreement effective as of January 24, 2018 between Dr. Brian Windsor and the Registrant, as amended on December 20, 2018 and September 26, 2019
10.9*+   Consulting Agreement dated April 23, 2018 between Glenn Mattes and the Registrant

 

2

 

 

Exhibit No.   Description of Document
10.10*   Lease Agreement dated October 19, 2018
10.11*+   Executive Employment Agreement dated December 20, 2018 between Glenn Mattes and the Registrant
10.12*   Securities Purchase Agreement dated May 16, 2019 by and among the Registrant and the Buyers named therein
10.13*   Amendment No. 1 to Patent License Agreement dated November 30, 2018 between the Registrant and The University of Texas at Austin
10.14*+   Employment Agreement, dated February 15, 2019, by and between the Registrant and Kirk Coleman
21.1*   List of Subsidiaries
23.1*   Consent of Marcum LLP, Independent Registered Public Accounting Firm
23.2   Consent of Greenberg Traurig, LLP (included in Exhibit 5.1)
24.1*   Power of Attorney

 

 

*Previously filed

 

+Indicates management compensatory plan, contract or arrangement

 

3

 

 

SIGNATURES

 

Pursuant to the requirementsof the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,thereunto duly authorized, in the City of Austin, Texas on this 11th day of October 2019.

 

    TFF PHARMACEUTICALS, INC.
     
    /s/ Glenn Mattes
    Glenn Mattes
Chief Executive Officer and Director
(Principal Executive Officer)

 

Pursuant to the requirementsof the Securities Act of 1933, this registration statement on Form S-1 has been signed by the following persons in the capacitiesand on the dates indicated.

 

Signature   Title   Date
         
/s/ Glenn Mattes    President,   October 11, 2019
Glenn Mattes   Chief Executive Officer
and Director
(Principal Executive Officer)
   
         
/s/ Kirk Coleman   Chief Financial Officer,   October 11, 2019
Kirk Coleman   Treasurer and Secretary
(Principal Financial and
Accounting Officer)
   
         
*   Chairman of the Board   October 11, 2019
Aaron Fletcher, Ph.D.        
         
*   Director   October 11, 2019
Brian Windsor, Ph.D.        
         
*   Director   October 11, 2019
Robert S. Mills, Jr.        
         
*   Director   October 11, 2019
Stephen C. Rocamboli        
         
*   Director   October 11, 2019
Harlan Weisman, M.D.        
         
*   Director   October 11, 2019
Randy Thurman        

 

*By: /s/ Glenn Mattes  
  Glenn Mattes  
  Attorney-in-Fact  

 

 

4